secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0001764013-23-000114
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant announces positive initial Phase 1 data for IMVT-1402 with IgG reductions and no albumin or LDL-C changes
--------------------------------------------------------------------------------

- Mean total IgG reduction of 63% after four weekly 300 mg SC doses of IMVT-1402 in Phase 1 MAD cohort.
- No decrease in serum albumin below baseline or increase in LDL-C above baseline observed after 4 weeks.
- Subcutaneous doses of IMVT-1402 achieved peak IgG reductions similar to those previously seen with batoclimab.
- All adverse events were mild or moderate; dosing for 600 mg cohort has recently begun.
- Immunovant hosted a conference call and webcast on September 26, 2023 to discuss the data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401323000114/0001764013-23-000114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401323000114/imvt-20230926.htm
  HTML page:      https://secwatch.observer/filing/0001764013-23-000114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer